Mode
Text Size
Log in / Sign up
Phase 2 Completed N=12 Treatment

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Source: ClinicalTrials.gov NCT01196871 ↗
Enrolled (actual)
12
Serious AEs
1.7%
Results posted
Nov 2018
Primary outcomePrimary: Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat — 1132.72; 4730.47; 384.20; 2409.02 hr*[nmol/hr/mL]

Summary

The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl) (migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of agalsidase and the effects of agalsidase on the safety and PK of migalastat 150 mg.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat
1132.72; 4730.47; 384.20; 2409.02; 5670.76; 787.23
PRIMARY
Change In Maximum Observed Plasma Concentration (Cmax) For Active α-Gal A Levels After Administration Of Migalastat
514.18; 1682.13; 309.02; 684.36; 1775.12; 370.91
PRIMARY
Change In Time To Maximum Observed Plasma Concentration (Tmax) And Terminal Elimination Half-life (T1/2) For Active α-Gal A Levels After Administration Of Migalastat
2.07; 2.16; 0.75; 3.00; 2.58; 0.75
PRIMARY
Change In AUC For Total α-Gal A Protein Levels After Administration Of Migalastat
57187.48; 29905.87; 42256.74; 16229.13; 17200.63; 28770.37
PRIMARY
Change In Percentage Of AUCinfinity Extrapolated From The Last Time Point At Which Concentration Is Quantified To Infinity (AUCextrapolated %) For Total α-Gal A Protein Levels After Administration Of Migalastat
60.50; 27.55; 73.26; 8.49; 12.30; 58.37
PRIMARY
Change In Cmax For Total α-Gal A Protein Levels After Administration Of Migalastat
7159.13; 5156.74; 3813.49; 3141.84; 3983.05; 3587.46
PRIMARY
Change In Tmax And T1/2 For Total α-Gal A Protein Levels After Administration Of Migalastat
2.07; 2.16; 0.75; 3.00; 2.50; 0.75
PRIMARY
Change In AUC For Migalastat After Administration Of Agalsidase
15717.87; 9413.79; 16051.81; 49483.00; 30450.61; 33920.71
PRIMARY
Change In Cmax For Migalastat After Administration Of Agalsidase
1690.00; 1295.67; 2047.50; 4750.00; 3763.33; 4455.00
PRIMARY
Change In Tmax And T1/2 For Migalastat After Administration Of Agalsidase
3.70; 3.33; 3.02; 4.00; 3.33; 4.50
SECONDARY
Change From Baseline To Day 7 In Active α-Gal A In Skin Following Treatment With Agalsidase Alone And Co-administration With Migalastat
334; 857; 121; 89; 1936; 18

Eligibility Criteria

Inclusion Criteria

  • Male diagnosed with Fabry disease and between 18 and 65 years of age, inclusive
  • Body mass index between 18-35 kg per meter squared
  • Had initiated treatment with agalsidase at least 1 month prior to screening, and had received at least 2 infusions before screening
  • Had stable dose level, dosing regimen, and form of agalsidase for at least 1 month before screening
  • Had an estimated creatinine clearance greater than or equal to 50 milliliters (mL)/minute at screening
  • Agreed to use medically accepted methods of contraception during the study and for 30 days after study completion
  • Were willing and able to provide written informed consent

Exclusion Criteria

  • Had a documented transient ischemic attack, ischemic stroke, unstable angina, or myocardial infarction within the 3 months before screening
  • Had clinically significant unstable cardiac disease (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)
  • History of allergy or sensitivity to study drug (including excipients) or other iminosugars (such as miglustat, miglitol)
  • Required a concomitant medication prohibited by the protocol: Glyset® (miglitol), or Zavesca® (miglustat)
  • Any investigational/experimental drug or device within 30 days of screening, except for use of investigational enzyme replacement therapy for Fabry disease
  • Had any intercurrent illness or condition that might have precluded the participant from fulfilling the protocol requirements or suggested to the investigator that the potential participant might have had an unacceptable risk by participating in this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01196871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search